We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Biofile Acquires Biofons' ELISA Products

By Labmedica staff writers
Posted on 29 Dec 2004
All rights to the enzyme-linked immunosorbent assay (ELISA) and indirect fluorescent antibody (IFA) products of Biofons (Turku, Finland) have been acquired by Biofile Ltd. More...
(also in Turku). No financial details were disclosed.

All key Biofons personnel from manufacturing and customer service related to the ELISA business have also been transferred from Biofons to Biofile. Biofile now owns all rights to the Biofons brand. Biofile develops, manufactures, and markets innovative diagnostic tests for autoimmune and infectious diseases for private and public clinical laboratories worldwide.

According to Biofile, the new product line will strengthen the company's existing product line. It includes the Biofons celiac disease panel and inflammatory bowel disease panel. The celiac disease panel includes five different tests: anti-gliadin IgA and IgG, anti-transglutaminase IgA and IgG, and endomysium IgA (hUC) IFA test.





Related Links:
Biofile
Biofons

New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Electrolyte Analyzer
CBS-4000 (CBS-400)
New
Rapid Sepsis Test
SeptiCyte RAPID
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.